



Singapore Institute of Advanced Medicine Holdings Ltd.

1 Biopolis Drive

#02-01 Amnios

Singapore 138622

For Immediate Release

Singapore Institute of Advanced Medicine Holdings Ltd's IPO garners strong support from investors

- Placement Shares under the Invitation were fully subscribed for
- Public Offer Shares was approximately 1.39 times subscribed
- Gross proceeds of approximately S\$26.2 million raised through the Invitation
- Trading of SAM Holdings' shares to commence at 9:00 a.m. (Singapore Time) on 16 February 2024 under the ticker "9G2" on the Catalist Board of the SGX-ST

Singapore, 15 February 2024 – Singapore Institute of Advanced Medicine Holdings Ltd. ("**SAM Holdings**" or the "**Company**", and together with its subsidiaries, the "**Group**"), which aims to become a comprehensive one-stop ambulatory cancer centre, is pleased to announce that it has received strong support for its initial public offering ("**IPO**") and its Invitation Shares are fully subscribed.

Following the close of the Application List in Singapore at 12.00 noon (Singapore time) on 14 February 2024, the Board of Directors of the Company (the "**Board**") is pleased to announce the following:

The Placement was fully subscribed for.

As at the close of the Application List in Singapore at 12.00 noon (Singapore time) on 14 February 2024, there were 286 valid applications made by way of Application Forms or Electronic Applications for an aggregate of 6,141,000 Public Offer Shares. Based on the 4,415,000 Invitation Shares available to the public for subscription, the Public Offer was approximately 1.39 times subscribed.

Based on the aggregate number of 114,000,000 Invitation Shares under the Invitation, the valid applications received under the Public Offer as at the close of the Invitation and the aggregate valid applications received under the Placement, the Invitation was approximately 1.01 times subscribed.

Taking into consideration the valid applications for the Invitation Shares, PrimePartners Corporate Finance Pte. Ltd., the Sponsor, Issue Manager, Underwriter and Placement Agent, in consultation with the Company, has decided that the aggregate number of 114,000,000 Invitation Shares will be re-allocated as follows:



Singapore Institute of Advanced Medicine Holdings Ltd.

1 Biopolis Drive

#02-01 Amnios

Singapore 138622

- 109,126,000 Invitation Shares pursuant to the Placement; and
- 4,874,000 Invitation Shares pursuant to the Public Offer.

Trading of SAM Holdings' shares is expected to commence at 9.00 a.m. (Singapore time) on 16 February 2024, subject to the SGX-ST being satisfied that all conditions necessary for commencement of trading in the Shares on a "ready" basis have been fulfilled.

Dr Djeng Shih Kien, the Executive Director and CEO, and founder of SAM Holdings, said, *"As we embark on this journey, fueled by the success of our IPO, we believe that our subscription is not just a testament to our past achievements, but a vote of confidence for the growth and impact yet to come. We aim to help our patients achieve better outcomes and better quality of life. The team is excited for a future where innovation, compassion, and collaboration converge in this fight against cancer."*

The Board wishes to thank all applicants who have applied for the Invitation Shares, the relevant authorities and all who have helped in one way or another in the Company's IPO, for their support and assistance.

- - End - -



Singapore Institute of Advanced Medicine Holdings Ltd.

1 Biopolis Drive

#02-01 Amnios

Singapore 138622

About Singapore Institute of Advanced Medicine Holdings Ltd. (“SAM Holdings”)

Incorporated in 2011, SAM Holdings is a healthcare service provider using advanced technology for early and accurate diagnosis and offering appropriate treatments to achieve better outcomes and quality of life for our patients. The Group’s services cater to a wide spectrum of diseases and health conditions including, but not limited to, cancer, neurodegenerative and cardiovascular disease detection, and treatment. The Group is primarily engaged in two key business segments: (i) Medical Diagnostics and Treatments; and (ii) Radiation Therapy and Medical Oncology Services.

The goal is to create a comprehensive one-stop ambulatory cancer centre to undertake the challenges to fight cancer. The Group aims to do this by bringing together a dedicated team of professionals and experts from the industry who will empower them to take away the fear of cancer by finding the answers and solutions for the diagnosis, treatment, and ongoing quality of life improvements for cancer patients.

For more information, please visit SAM Holdings’ website at <http://www.advancedmedicine.sg>

**Issued for and on behalf of Singapore Institute of Advanced Medicine Holdings Ltd.
By Financial PR Pte Ltd**

For more information please contact:

Shivam SARAF / Kamal SAMUEL / Urvija DIWAN

Financial PR Pte Ltd

Tel: 6438 2990 / Fax: 6438 0064

E-mail: shivam@financialpr.com.sg / kamal@financialpr.com.sg / urvija@financialpr.com.sg

Disclaimer: This press release is for information only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities or an inducement or recommendation to enter into any investment activity, nor shall any part or all of this press release form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. None of the Company nor any of its subsidiaries, controlling persons, PrimePartners Corporate Finance Pte. Ltd., nor any of their respective directors, officers, partners, employees, agents, representatives or advisers makes any representation or warranty (express or implied) regarding, or assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. Readers should read the offer document registered with the Singapore Exchange Securities Trading Limited, acting as agent on behalf of the Monetary Authority of Singapore, on 2 February 2024 before making any investment decision. If any reader is in any doubt as to the action, he/she/it should take, he/she/it should consult his/her/its legal, financial, tax or other professional adviser(s).



Singapore Institute of Advanced Medicine Holdings Ltd.

1 Biopolis Drive

#02-01 Amnios

Singapore 138622

This press release has been prepared by the Company and reviewed by the Sponsor, PrimePartners Corporate Finance Pte. Ltd., in compliance with Rules 226(2)(b) and 753(2) of the Catalist Rules.

This press release and its contents have been reviewed by the Sponsor, for compliance with the relevant rules of the SGX-ST. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr. Mark Liew, Chief Executive Officer and Executive Director, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.